GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 36, No. 15_suppl ( 2018-05-20), p. e12550-e12550
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2018
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    American Society of Clinical Oncology (ASCO) ; 2013
    In:  Journal of Clinical Oncology Vol. 31, No. 15_suppl ( 2013-05-20), p. e22113-e22113
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 31, No. 15_suppl ( 2013-05-20), p. e22113-e22113
    Abstract: e22113 Background: We evaluated the contrast effects of Sonazoid in tumor tissue according to brightness intensity, in cases pathologically diagnosed with breast cancer. Methods: Six cases of ductal carcinoma in situ (DCIS) and seven cases of invasive ductal carcinoma (IDC) diagnosed with needle or Mammotome biopsy between September and December 2012 were examined. The mean ages of the DCIS and IDC cases were 51.7 ± 11.8 years and 62.5 ± 15.7 years respectively. In the IDC cases, tumor diameter was 6-10 mm in three cases, 11-20 mm in three cases and over 50 mm in one case. Two IDC cases were of the luminal A subtype, three cases were luminal B and two cases were triple negative. The ultrasound equipment used was HI VISION ASCENDUS (Hitachi Medical Corporation). The contrast agent, Sonazoid, was administered intravenously at 0.01ml/kg, and for approximately 50 seconds, the tumor sections were fixated and underwent imaging. Sonazoid brightness in the tumor was digitized and a time intensity curve was created based on brightness intensity and time changes. Early and peak contrast brightness was then compared in order to objectively examine changes in contrast effects. Results: Peak brightness was 1.6 ± 0.3 times and 4.8 ± 3.2 times the early brightness in DCIS and IDC cases respectively, indicating a more significant increase in IDC cases (P 〈 0.05). Comparison according to subtype in IDC cases also revealed a strong increasing trend in triple negative cases, with results showing that peak brightness compared to early brightness was 9.1 times greater in triple negative cases, 2.7 times greater in luminal A cases and 3.3 times greater in luminal B cases. Classification of IDC cases according to nuclear grade (NG) found that peak brightness was 6.2 times greater than early brightness in NG3 cases, 5.7 times greater in NG2 cases and 1.7 times greater in NG1 cases. Conclusions: Brightness intensity, when digitized and analyzed, could be applied to the differential diagnosis of DCIS and IDC. Brightness intensity may also exhibit correlations with subtypes and NG, suggesting that it could be applied to malignancy grading, as well as the prediction of effects of drug therapy and effect measurement.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2013
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 32, No. 15_suppl ( 2014-05-20), p. 1066-1066
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2014
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 75, No. 9_Supplement ( 2015-05-01), p. P1-02-11-P1-02-11
    Abstract: Background: The aim of this study was to evaluate the significance of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for predicting the underestimation of invasive breast cancer in cases of ductal carcinoma in situ (DCIS) at needle biopsy. Patients and Methods: Of 83 consecutive cases with diagnoses of DCIS at primary needle biopsy who underwent curative surgery between 2010 and 2013, the association between the maximum standardized uptake value (SUVmax) on FDG-PET/CT before excision and the underestimation of invasive breast cancer was examined. Results: There were 29 (34.9%) cases diagnosed to have invasive breast cancer at excision. Receiver operating characteristics (ROC) curve analysis showed the cutoff value of SUVmax to predict underestimation of invasive breast cancer was 1.6. The rates of underestimation were 61.5% for patients with a tumor of SUVmax & gt; 1.6 and 11.4% for patients with a tumor SUV max ≤ 1.6 (p & lt;0.001). High value of SUVmax was significantly associated with symptomatic presentation (p & lt; 0.001), palpability (p & lt; 0.001), mass formation (p = 0.013), high Breast Imaging Reporting and Data System category (p = 0.011) and core needle biopsy (p = 0.007). In multivariate analysis, high SUVmax was only significant predictive factor of underestimation of invasive breast cancer (HR 11.7, 95% CI 3.70-37.0, p & lt; 0.001). Association between each preoperative variable and underestimation of invasive component in multivariate analysis in cases of DCIS diagnosed at needle biopsyVariables HR (95% CI)P valuePresentationsymptomatic vs. screening detected1.64 (0.43-6.22)0.47Palpableyes vs. no1.54 (0.36-6.69)0.58Lesion size & lt; 2cm vs. ≥ 2cm1.23 (0.34-4.40)0.76Mass formationyes vs. no1.28 (0.36-4.44)0.7BI RADS category5 vs. 3, 42.92 (0.80-10.7)0.11Biopsy devicemammotome biopsy vs. CNB2.16 (0..64-7.30)0.21Nuclear gradehigh vs. not highhigh vs. not high 2.24 (0.51-9.78)0.29SUVmaxhigher vs. lower11.7 (3.70-37.0) & lt; 0.001BI RADS, Breast Imaging Reporting and Data System; DCIS, ductal carcinoma in situ; IBC, invasive breast cancer; SUVmax, maximum standardized uptake value Conclusion: SUVmax on FDG-PET/CT is useful for predicting the underestimation of invasive breast cancer in cases of DCIS at needle biopsy. Citation Format: Hideo Shigematsu, Takayuki Kadoya, Noriko Yoshimura, Keiko Kajitani, Akiko Emi, Noriko Masumoto, Rumi Haruta, Tsuyoshi Kataoka, Morihito Okada. Role of FDG-PET/CT in prediction of underestimation of invasive breast cancer in cases of ductal carcinoma in situ diagnosed at needle biopsy [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AAC R San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-02-11.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2015
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: World Journal of Surgical Oncology, Springer Science and Business Media LLC, Vol. 9, No. 1 ( 2011-12)
    Type of Medium: Online Resource
    ISSN: 1477-7819
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2011
    detail.hit.zdb_id: 2118383-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 35, No. 15_suppl ( 2017-05-20), p. e12097-e12097
    Abstract: e12097 Background: Unlike whole body (WB) 18F-fluorodeoxyglucose (FDG) PET, dedicated breast PET (DBPET) enables detailed high-resolution images within the breast and quantitative assessment using SUV. We aimed to determine whether DBPET can detect ductal carcinoma in situ (DCIS) and predict the malignancy and neoplastic progress of invasive breast cancer. Methods: We investigated 155 consecutive patients with breast cancer who underwent concurrent DB– and WB– PET (Elmammo®) between January and November 2016. All DB– and WB– PET images were quantified based on standard uptake values (SUV). We also assessed 12 patients with ring-like uptake (RU) without central FDG accumulation in invasive breast cancers on DBPET images. Results: The SUV (means ± SD) determined from DB– and WB– PET images of breast cancer were 8.2 ± 7.7 and 3.1 ± 3.3 respectively. We detected DCIS in DB- and WB– PET images from 22 (84.7%) and 15 (57.6%) of 26 among the 155 patients, respectively (p = 0.003). The SUV on WB– PET images was significantly higher for NG3 than for NG1-2 (p = 0.004), and for high (≥ 20%) than low ( 〈 20%) Ki67 (p = 0.003), and significantly lower for Luminal A than Luminal B, HER2 and triple-negative cancer (p 〈 0.05 for all three). The SUV for NG (p = 0.002), Ki67 (p = 0.001) and the luminal (p 〈 0.05) type also significantly differed in DBPET images. RU without central FDG accumulation was evident in DbPET images of 12 patients, all of whom had Ki67 ≥ 20 (p = 0.0001), two had NG1-2 and 10 had NG3 (p = 0.005), one had clinical T1, 11 had T2 (p = 0.0004), five had clinical N0 and seven had N1 (p = 0.03). RU was associated with high-grade malignancy and neoplastic progress. Conclusions: The detection rate of DBPET was excellent for DCIS. The RU on DBPET offers predictive value for high-grade malignancy and the neoplastic progress of invasive breast cancer. Thus, DBPET might help to determine therapeutic strategies.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2017
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    Springer Science and Business Media LLC ; 2012
    In:  Breast Cancer Research and Treatment Vol. 134, No. 1 ( 2012-7), p. 139-155
    In: Breast Cancer Research and Treatment, Springer Science and Business Media LLC, Vol. 134, No. 1 ( 2012-7), p. 139-155
    Type of Medium: Online Resource
    ISSN: 0167-6806 , 1573-7217
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2012
    detail.hit.zdb_id: 2004077-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 75, No. 9_Supplement ( 2015-05-01), p. P5-03-04-P5-03-04
    Abstract: Background: A biopsy of lung nodules in patients, who had received previous surgery for breast cancer, can be performed with three aims: to confirm that the lesion is lung metastasis, to confirm the diagnosis of other diseases including primary lung cancer, and to reassess tumor’s characteristics. Discordance in estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status between primary breast cancer and metastatic lesions has been reported. The aim of this study was to assess the role of lung biopsy in the diagnosis and to determine the changes in hormonal receptor and HER2 status of the metastatic lesions. Methods: A total of 38 consecutive patients who underwent surgery in 31 or transbronchial lung biopsy (TBLB) in 7 for lung nodules between 1997 and 2014 after curative operation for breast cancer were reviewed. Results: Eighteen patients (47%) had a solitary lung nodule. The pathologic diagnoses of lung nodules were lung metastases of breast cancer in 20 patients, primary lung tumor in 14 (Adenocarcinoma in 10; Large cell carcinoma in 2; Small cell carcinoma and Carcinoid tumor in 1 each), and other diagnoses in 4 (Inflammation and organizing pneumonia in 2 each). Median follow up duration were 118.8 months in metastatic breast cancer patients and 105.3 months in other histology patients (p=0.392). The average disease-free interval from the surgery for primary breast cancer were 68.6 months in metastatic breast cancer patients and 66.3 months in other histology patients (p=0.897). The 10-year survival rate after the surgery for primary breast cancer was significantly longer in other histology patients (92.3%), including primary lung cancer patients than in metastatic breast cancer patients (55.1%) (p=0.0308). In 20 cases of metastatic breast cancer, rates of discordance were 5%, 10% and 10% for ER gain, PgR gain and HER2 loss, respectively. Sixteen of patients maintained the same tumor phenotype, whereas 4 changed during progression. Especially, 2 cases of ER, PgR gain could receive endocrine therapy instead of chemotherapy. Conclusion: As lung nodules that appear in breast cancer patients are not always lung metastases, the pathologic diagnosis should be confirmed, and surgery is an option for the pathologic confirmation. Furthermore, discordance in biomarker status between primary breast cancer and the lung metastasis occurred in 20% of cases. It is necessary for clinicians to check biomarker status in recurrent breast cancer patients as it may assist a shift in the treatment plan. Citation Format: Kazuo Matsuura, Takayuki Kadoya, Norio Masumoto, Hideo Shigematsu, Akiko Emi, Keiko Kajitani, Morihito Okada, Tsuyoshi Kataoka, Rumi Haruta, Koji Arihiro, Midori Noma, Toshiyuki Itamoto. The role of lung biopsy in the management of lung nodules in breast cancer patients [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P5-03-04.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2015
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2015
    In:  Cancer Research Vol. 75, No. 9_Supplement ( 2015-05-01), p. P1-02-04-P1-02-04
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 75, No. 9_Supplement ( 2015-05-01), p. P1-02-04-P1-02-04
    Abstract: Objectives This study aimed to determine whether or not signal intensity caused by the contrast effects of Contrast-enhanced ultrasonography (CEUS) using perflubutane could predict malignancy grades of invasive breast cancer. Methods Fifty-four patients with clinical stages I – III breast cancer between April 2013 and April 2014 underwent CEUS using perflubutane. We analyzed the assciation between contrast-effect intensity and contrast time in CEUS and the prognostic factors based on tumor size, nodal status and immunohistochemical markers (ER, HER-2 status, nuclear grade, Ki-67) in breast cancer. Results Time to washout of time required to reach plateau intensity from the start of the maximum intensity was significantly associated with the Ki-67 value (p = 0.03). Also, A parameter of intratumoral blood perfusion, peak intensity (PI), was significantly associated with the Ki-67 value (p = 0.006) and ER status (p = 0.002) (Table 1), but not with tumor size (cT; p = 0.25, pT; 0.96), node status (p = 0.99), HER-2 status (p = 0.32) and nuclear grade (p = 0.61). Table 1. Relationship between changes in temporal contrast over time as a perfusion parameter and clinicopathological factorsFactorn(%)Peak intensityMean ± SDpMean age ± SD (y)53.8 ± 13.5 & lt; 50 y30 (55.6)65.5 ± 25.40.50≥ 50 y24 (44.4)61.1 ± 21.5NG1 or 219 (35.2)65.8 ± 28.00.61335 (64.8)62.4 ± 21.2Ki67 & lt; 3024 (44.4)53.8 ± 22.40.006≥ 3030 (55.6)71.4 ±21.9ERNegative13 (31.7)58.2 ± 20.90.002Positive41 (68.3)80.5 ± 24.6HER2Negative47 (87.0)62.3 ± 24.00.32Positive7 (13.0)71.9 ± 20.5ER: estrogen receptor, HER2: human epidermal growth factor receptor 2, NG: nuclear grade. Also, Thirty-eight, 7, and 9 patients had luminal, HER-2-positive and triple-negative tumors, respectively. The PI values for these tumors were 56.8 ± 20.9, 71.9 ± 20.5, and 85.7 ± 23.2, respectively. And, the PI value was significantly greater in the triple-negative, than in luminal tumors (p = 0.001). Table 2. Relationship between signal intensity as a perfusion parameter and tumor subtypesTumor subtypenPeak intensitySubtypeMean ± SDp *Luminal3856.8 ± 20.9HER-2-positive771.9 ± 20.50.09Triple-negative985.7 ± 23.20.001 Furthermore, PI significantly correlated with the Ki-67 value (Spearman r = 0.54, P = 0.00002). Conclusions These findings indicated that PI has excellent predictive value for grade malignancy in breast cancer and might help to determine appropriate therapeutic strategies. Key points • Contrast-enhanced ultrasonography (CEUS) enables the real-time evaluation of detailed hemodynamics in breast cancer. • Peak intensity (PI) was significantly associated with Estrogen Receptors and Ki-67 assessed by immunohistochemistry. • PI significantly correlated with the Ki-67 value, indicating that PI reflects the grade of proliferative activity in tumors. • Analyses of contrast-effect intensity will be applied to evaluate grades of malignancy and determine treatment strategies. Citation Format: Noriko Yoshimura, Norio Masumoto, Ai Amioka, Keiko Kajitani, Hideo Shigematsu, Akiko Emi, Takayuki Kadoya, Tsuyoshi Kataoka, Rumi Haruta, Morihito Okada. Impact of perflubutane-enhanced ultrasonography for evaluating malignancy grade of breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-02-04.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2015
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    Japan Association of Breast Cancer Screening ; 2019
    In:  Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening) Vol. 28, No. 2 ( 2019), p. 89-92
    In: Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening), Japan Association of Breast Cancer Screening, Vol. 28, No. 2 ( 2019), p. 89-92
    Type of Medium: Online Resource
    ISSN: 0918-0729 , 1882-6873
    Language: English
    Publisher: Japan Association of Breast Cancer Screening
    Publication Date: 2019
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...